A study of the efficacy of glutamine and prebiotics in the patients with inflammatory bowel disease
Not Applicable
- Conditions
- lcerative colitis
- Registration Number
- JPRN-UMIN000004306
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Department of Diabetes and Clinical Nutrition Graduate School of Medicine, Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have severe hepatic or renal disease 2) Patients whose conditions of ulcerative colitis are unstable 3) Patients who have history of gastrectomy or extensive enterectomy 4) Patients who have malignant tumor under treatment 5) Patients who are judged as not appropriate for participation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie glutamine and prebiotic efficacy in ulcerative colitis?
How do glutamine and prebiotics compare to standard-of-care treatments for ulcerative colitis?
Which biomarkers predict response to glutamine and prebiotic therapy in IBD patients?
What adverse events are associated with glutamine and prebiotic supplementation in IBD?
Are there combination therapies involving glutamine and prebiotics for IBD treatment?